Spoken Alpha
UTHR
UNITED THERAPEUTICS Corp
Overview
United Therapeutics develops and markets pharmaceutical therapies and medical devices to treat pulmonary arterial hypertension and other rare lung diseases, as well as a cancer immunotherapy.
UNITED THERAPEUTICS Corp is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $23.11B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 28, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-067 Q&A exchanges
- Q4 FY2025Earnings2026-02-255 Q&A exchanges
- Q3 FY2025Earnings2025-10-297 Q&A exchanges
- Q2 FY2025Earnings2025-07-309 Q&A exchanges
- Q1 FY2025Earnings2025-04-308 Q&A exchanges
- Q4 FY2024Earnings2025-02-266 Q&A exchanges
- Q3 FY2024Earnings2024-10-307 Q&A exchanges
- Q2 FY2024Earnings2024-07-317 Q&A exchanges
- Q1 FY2024Earnings2024-05-014 Q&A exchanges
- Q4 FY2023Earnings2024-02-216 Q&A exchanges
- Q3 FY2023Earnings2023-11-016 Q&A exchanges
- Q2 FY2023Earnings2023-08-027 Q&A exchanges
- Q1 FY2023Earnings2023-05-037 Q&A exchanges
- Q4 FY2022Earnings2023-02-226 Q&A exchanges
- Q3 FY2022Earnings2022-11-028 Q&A exchanges
- Q2 FY2022Earnings2022-08-036 Q&A exchanges
- Q1 FY2022Earnings2022-05-045 Q&A exchanges
- Q4 FY2021Earnings2022-02-275 Q&A exchanges
- Q3 FY2021Earnings2021-11-035 Q&A exchanges
- Q2 FY2021Earnings2021-08-048 Q&A exchanges
- Q1 FY2021Earnings2021-05-055 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-28EPS— vs $6.96—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-28 | — | $6.96 | — | — | — | — | EODHD |
Source: EODHD. UTHR reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks UTHR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.81 | $1.14 | -29.0% | +6.6% | +7.5% |
| Q4 FY2026 | $0.84 | $1.25 | -32.7% | -1.8% | 0.0% |
| Q3 FY2026 | $1.05 | $1.32 | -20.6% | +7.2% | +7.2% |
| Q2 FY2026 | $0.89 | $1.29 | -31.2% | +8.3% | +10.1% |
| Q1 FY2025 | $1.01 | $1.22 | -17.3% | +3.7% | +2.5% |
| Q4 FY2025 | $1.06 | $1.30 | -18.6% | +8.9% | +6.9% |
| Q3 FY2025 | $0.86 | $1.21 | -28.9% | +3.0% | +1.1% |
| Q2 FY2025 | $1.19 | $1.45 | -17.7% | +6.9% | +6.5% |
| Q1 FY2024 | $0.97 | $1.27 | -24.0% | +4.7% | +3.7% |
| Q4 FY2024 | $0.94 | $1.27 | -25.8% | +3.3% | +1.7% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Martine A RothblattCEO3 mo20 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
- James EdgemondCFO3 mo9 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2026
- Paul A MahonEVP & GENERAL COUNSEL2 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for UTHR.
$ curl https://api.spokenalpha.com/v1/companies/UTHRFAQ
Frequently asked about UTHR
Where can I find UNITED THERAPEUTICS Corp's (UTHR) earnings call transcripts?
Spoken Alpha indexes UTHR's earnings call transcripts at https://spokenalpha.com/companies/UTHR. Each call links to attributed speakers and parsed analyst Q&A. UNITED THERAPEUTICS Corp's own investor relations page is at https://ir.unither.com/.
When was UNITED THERAPEUTICS Corp's most recent earnings call?
UNITED THERAPEUTICS Corp (UTHR) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
What sector is UTHR in?
UNITED THERAPEUTICS Corp (UTHR) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).